Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity.
A 21 year old boy with borderline lepromatous leprosy and normal glucose-6-phosphate-dehydrogenase activity developed haemolytic anaemia, hepatitis and agranulocytosis following 19 weeks of multi-bacillary multi-drug therapy. With early administration of antibiotics and G-CSF our patient recovered without residual complications. All patients taking dapsone should be warned to discontinue the drug immediately in the event of fever, chills and sore throat occurring within the treatment period until further investigations are performed.
Ranawaka
Ranthilaka R
RR
Teaching Hospital Anuradhapura, Sri Lanka. ranthilaka37@yahoo.com
Mendis
Suresh
S
Weerakoon
Hema S
HS
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D005954:Glucosephosphate Dehydrogenase / Q000032:analysis; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male
D007917:Leprostatic Agents; D003622:Dapsone; D005954:Glucosephosphate Dehydrogenase